Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):599–604. doi: 10.1038/bjc.1993.393

EPIC: an effective low toxicity regimen for relapsing lymphoma.

T Hickish 1, A Roldan 1, D Cunningham 1, J Mansi 1, S Ashley 1, V Nicolson 1, M E Gore 1, D Catovsky 1, I E Smith 1
PMCID: PMC1968387  PMID: 8353050

Abstract

We have treated 40 patients was relapsed or resistant lymphoma with the combination of Etoposide, Prednisolone, Ifosfamide and Cisplatin (EPIC). Complete response was obtained in 11 patients (28%) with an overall response of 58%. The presence of bulky disease (P < 0.005), elevated LDH serum levels (P < 0.005), response to prior chemotherapy (P < 0.01) and B symptoms (P < 0.005) were significantly associated with response. However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival. The regimen was well tolerated with myelosuppression being the most common toxicity. Leucopenia < or 1,000 microliters-1 and thrombocytopenia < or = 25,000 microliters-1 developed in 27% and 4% of cycles respectively. There were no treatment related deaths. The EPIC regimen has equivalent activity to other reported cisplatin based regimens used in the treatment of recurrent lymphoma, but is associated with lower treatment related morbidity and mortality.

Full text

PDF
599

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Achterrath W., Niederle N., Raettig R., Hilgard P. Etoposide--chemistry, preclinical and clinical pharmacology. Cancer Treat Rev. 1982 Jun;9 (Suppl):3–13. doi: 10.1016/s0305-7372(82)80072-8. [DOI] [PubMed] [Google Scholar]
  2. Acker B., Hoppe R. T., Colby T. V., Cox R. S., Kaplan H. S., Rosenberg S. A. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol. 1983 Jan;1(1):11–16. doi: 10.1200/JCO.1983.1.1.11. [DOI] [PubMed] [Google Scholar]
  3. Appelbaum F. R., Sullivan K. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Hill R., Mortimer J., Neiman P. E., Sanders J. E. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol. 1987 Sep;5(9):1340–1347. doi: 10.1200/JCO.1987.5.9.1340. [DOI] [PubMed] [Google Scholar]
  4. Armitage J. O., Dick F. R., Corder M. P. Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant. Cancer Treat Rep. 1981 May-Jun;65(5-6):413–418. [PubMed] [Google Scholar]
  5. Cabanillas F., Hagemeister F. B., Bodey G. P., Freireich E. J. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982 Sep;60(3):693–697. [PubMed] [Google Scholar]
  6. Cabanillas F., Hagemeister F. B., McLaughlin P., Velasquez W. S., Riggs S., Fuller L., Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987 Mar;5(3):407–412. doi: 10.1200/JCO.1987.5.3.407. [DOI] [PubMed] [Google Scholar]
  7. Cabanillas F., Rodriguez V., Bodey G. P. Ifosfamide, methotrexate, and vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma. Cancer Treat Rep. 1980 Aug-Sep;64(8-9):933–937. [PubMed] [Google Scholar]
  8. Cabanillas F., Velasquez W. S., McLaughlin P., Jagannath S., Hagemeister F. B., Redman J. R., Swan F., Rodriguez M. A. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr;25(2 Suppl 2):47–50. [PubMed] [Google Scholar]
  9. Campbell A. B., Kalman S. M., Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep. 1983 Feb;67(2):169–172. [PubMed] [Google Scholar]
  10. Cavalli F., Jungi W. F., Nissen N. I., Pajak T. F., Coleman M., Holland J. F. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer. 1981 Nov 1;48(9):1927–1930. doi: 10.1002/1097-0142(19811101)48:9<1927::aid-cncr2820480902>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  11. DeVita V. T., Jr, Hubbard S. M., Young R. C., Longo D. L. The role of chemotherapy in diffuse aggressive lymphomas. Semin Hematol. 1988 Apr;25(2 Suppl 2):2–10. [PubMed] [Google Scholar]
  12. Dominici C., Petrucci F., Caroli S., Alimonti A., Clerico A., Castello M. A. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol. 1989 Jan;7(1):100–107. doi: 10.1200/JCO.1989.7.1.100. [DOI] [PubMed] [Google Scholar]
  13. Drewinko B., Brown B. W., Gottlieb J. A. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res. 1973 Dec;33(12):3091–3095. [PubMed] [Google Scholar]
  14. Drewinko B., Green C., Loo T. L. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1976 Nov;60(11):1619–1625. [PubMed] [Google Scholar]
  15. Durand R. E., Goldie J. H. Interaction of etoposide and cisplatin in an in vitro tumor model. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):673–679. [PubMed] [Google Scholar]
  16. Frei E., 3rd, Teicher B. A., Holden S. A., Cathcart K. N., Wang Y. Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 1988 Nov 15;48(22):6417–6423. [PubMed] [Google Scholar]
  17. Goldin A. Ifosfamide in experimental tumor systems. Semin Oncol. 1982 Dec;9(4 Suppl 1):14–23. [PubMed] [Google Scholar]
  18. Goss P. E., Shepherd F. A., Scott J. G., Warner E., Baker M. A., Sutton D., Farquharson H. A., Buick S., Sutcliffe S. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study. Ann Oncol. 1991 Jan;2 (Suppl 1):43–46. doi: 10.1093/annonc/2.suppl_1.43. [DOI] [PubMed] [Google Scholar]
  19. Hagemeister F. B., Tannir N., McLaughlin P., Salvador P., Riggs S., Velasquez W. S., Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987 Apr;5(4):556–561. doi: 10.1200/JCO.1987.5.4.556. [DOI] [PubMed] [Google Scholar]
  20. Hilgard P., Herdrich K., Brade W. Ifosfamide--current aspects and perspectives. Cancer Treat Rev. 1983 Sep;10 (Suppl A):183–192. doi: 10.1016/s0305-7372(83)80027-9. [DOI] [PubMed] [Google Scholar]
  21. Huijgens P. C., Ossenkoppele G. J., van der Lelie J., Thomas L. L., Wijngaarden M. J., Reijneke R. M. Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. Eur J Cancer Clin Oncol. 1988 Mar;24(3):483–486. doi: 10.1016/s0277-5379(98)90021-9. [DOI] [PubMed] [Google Scholar]
  22. Judson I. R., Wiltshaw E. Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen. Cancer Chemother Pharmacol. 1985;14(3):258–261. doi: 10.1007/BF00258129. [DOI] [PubMed] [Google Scholar]
  23. Kelsen D. P., Alcock N., Young C. W. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations. Am J Clin Oncol. 1985 Feb;8(1):77–80. [PubMed] [Google Scholar]
  24. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  25. Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6):716–735. [PubMed] [Google Scholar]
  26. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  27. Miller T. P., Grogan T. M., Dalton W. S., Spier C. M., Scheper R. J., Salmon S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan;9(1):17–24. doi: 10.1200/JCO.1991.9.1.17. [DOI] [PubMed] [Google Scholar]
  28. Nichols C. R., Williams S. D., Loehrer P. J., Greco F. A., Crawford E. D., Weetlaufer J., Miller M. E., Bartolucci A., Schacter L., Einhorn L. H. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991 Jul;9(7):1163–1172. doi: 10.1200/JCO.1991.9.7.1163. [DOI] [PubMed] [Google Scholar]
  29. Ozols R. F., Corden B. J., Jacob J., Wesley M. N., Ostchega Y., Young R. C. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984 Jan;100(1):19–24. doi: 10.7326/0003-4819-100-1-19. [DOI] [PubMed] [Google Scholar]
  30. Ozols R. F., Ihde D. C., Linehan W. M., Jacob J., Ostchega Y., Young R. C. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988 Jun;6(6):1031–1040. doi: 10.1200/JCO.1988.6.6.1031. [DOI] [PubMed] [Google Scholar]
  31. Ozols R. F., Ostchega Y., Myers C. E., Young R. C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985 Sep;3(9):1246–1250. doi: 10.1200/JCO.1985.3.9.1246. [DOI] [PubMed] [Google Scholar]
  32. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pfreundschuh M. G., Schoppe W. D., Fuchs R., Pflüger K. H., Loeffler M., Diehl V. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep. 1987 Dec;71(12):1203–1207. [PubMed] [Google Scholar]
  34. Philip T., Armitage J. O., Spitzer G., Chauvin F., Jagannath S., Cahn J. Y., Colombat P., Goldstone A. H., Gorin N. C., Flesh M. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987 Jun 11;316(24):1493–1498. doi: 10.1056/NEJM198706113162401. [DOI] [PubMed] [Google Scholar]
  35. Philip T., Chauvin F., Bron D., Guglielmi C., Hagenbeek A., Coiffier B., Gisselbrecht C., Kluin Nelemans J. C., Somers R., Misset J. C. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol. 1991 Jan;2 (Suppl 1):57–64. doi: 10.1093/annonc/2.suppl_1.57. [DOI] [PubMed] [Google Scholar]
  36. Phillips G. L., Fay J. W., Herzig R. H., Lazarus H. M., Wolff S. N., Lin H. S., Shina D. C., Glasgow G. P., Griffith R. C., Lamb C. W. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood. 1990 Feb 15;75(4):831–838. [PubMed] [Google Scholar]
  37. Plooy A. C., van Dijk M., Lohman P. H. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984 May;44(5):2043–2051. [PubMed] [Google Scholar]
  38. Posner M. R., Skarin A. T., Clark J., Ervin T. J. Phase I study of continuous-infusion cisplatin. Cancer Treat Rep. 1986 Jul;70(7):847–850. [PubMed] [Google Scholar]
  39. Press O. W., Livingston R., Mortimer J., Collins C., Appelbaum F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol. 1991 Mar;9(3):423–431. doi: 10.1200/JCO.1991.9.3.423. [DOI] [PubMed] [Google Scholar]
  40. Reddel R. R., Kefford R. F., Grant J. M., Coates A. S., Fox R. M., Tattersall M. H. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982 Jan;66(1):19–23. [PubMed] [Google Scholar]
  41. Rodriguez V., McCredie K. B., Keating M. J., Valdivieso M., Bodey G. P., Freireich E. J. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep. 1978 Apr;62(4):493–497. [PubMed] [Google Scholar]
  42. Roelofs R. I., Hrushesky W., Rogin J., Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul;34(7):934–938. doi: 10.1212/wnl.34.7.934. [DOI] [PubMed] [Google Scholar]
  43. Santoro A., Viviani S., Valagussa P., Bonfante V., Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23–26. [PubMed] [Google Scholar]
  44. Schabel F. M., Jr, Trader M. W., Laster W. R., Jr, Corbett T. H., Griswold D. P., Jr cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459–1473. [PubMed] [Google Scholar]
  45. Scheulen M. E., Bremer K., Niederle N., Seeber S. Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy. Cancer Treat Rev. 1983 Sep;10 (Suppl A):137–143. doi: 10.1016/s0305-7372(83)80019-x. [DOI] [PubMed] [Google Scholar]
  46. Takvorian T., Canellos G. P., Ritz J., Freedman A. S., Anderson K. C., Mauch P., Tarbell N., Coral F., Daley H., Yeap B. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11;316(24):1499–1505. doi: 10.1056/NEJM198706113162402. [DOI] [PubMed] [Google Scholar]
  47. Taylor R. E., McElwain T. J., Barrett A., Peckham M. J. Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother Pharmacol. 1982;7(2-3):175–177. doi: 10.1007/BF00254543. [DOI] [PubMed] [Google Scholar]
  48. Tseng A., Jr, Jacobs C., Coleman C. N., Horning S. J., Lewis B. J., Rosenberg S. A. Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. Cancer Treat Rep. 1987 May;71(5):475–478. [PubMed] [Google Scholar]
  49. Velasquez W. S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F. B., Redman J. R., Swan F. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117–122. [PubMed] [Google Scholar]
  50. Vose J. M., Bierman P. J., Armitage J. O. Hodgkin's disease: the role of bone marrow transplantation. Semin Oncol. 1990 Dec;17(6):749–757. [PubMed] [Google Scholar]
  51. Zwelling L. A., Kohn K. W. Mechanism of action of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1439–1444. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES